Does it matter how blood pressure is lowered in patients with metabolic risk factors?

Journal of the American Society of Hypertension

Volumn 2, Issue 4 SUPPL., 2008, Pages

  Sharma, Arya M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Abdominal obesity; antihypertensive therapy; RAS; telmisartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; FELODIPINE; HYDROCHLOROTHIAZIDE PLUS METOPROLOL; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; RAMIPRIL; SIBUTRAMINE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ABDOMINAL OBESITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

EID: 46849122195     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2008.03.006     Document Type: Article

References (35)

1. Sharma A.M. Obesity and cardiovascular risk. Growth Horm IGF Res 13 (2003) S10-S17
2. Must A., Spadano J., Coakley E.H., Field A.E., Colditz G., and Dietz W.H. The disease burden associated with overweight and obesity. JAMA 282 (1999) 1523-1529
3. Stamler J., Stamler R., Riedlinger W.F., Algera G., and Roberts R.H. Hypertension screening of 1 million Americans. Community Hypertension Evaluation Clinic (EHEC) Program, 1973 through 1975. JAMA 235 (1976) 2299-2306
4. Kannel W.B., Garrison R.J., and Dannenberg A.L. Secular blood pressure trends in normotensive persons: the Framingham Study. Am Heart J 125 (1993) 1154-1158
5. Anderson J.W., and Konz E.C. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 9 (2001) 326S-334S
6. Mertens I.L., and van Gaal L.F. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res 8 (2000) 270-278
7. World Health Organization. Report of a WHO Consultation on Obesity. Obesity: Preventing and Managing the Global Epidemic (1998), World Health Organization, Geneva, Switzerland 43-44 56
8. Alexander L.M. Desirable therapeutic characteristics of an optimal antihypertensive agent. Drugs 66 (2006) 1239-1252
9. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet 364 (2004) 937-952
10. Douketis J.D., Paradis G., Keller H., and Martineau C. Canadian guidelines for body weight classification in adults: application in clinical practice to screen for overweight and obesity and to assess disease risk. CMAJ 172 (2005) 995-998
11. Yusuf S., Hawken S., Ounpuu S., Bautista L., Franzosi M.G., Commerford P., et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366 (2005) 1640-1649
12. Sharma A.M. Adipose tissue: a mediator of cardiovascular risk. Int J Obes 26 (2002) S5-S7
13. Lau D.C.W., Douketis J.D., Morrison K.M., Hramiak I.M., Sharma A.M., Ur E., and Obesity Canada Clinical Practice Guidelines Expert Panel. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. [summary]. CMAJ 176 (2007) S1-S13
14. Scholze J., Grimm E., Herrmann D., Unger T., and Kintscher U. Optimal treatment of obesity-related hypertension. The Hypertension-Obesity-Sibutramine (HOS) Study. Circulation 115 (2007) 1991-1998
15. United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317 (1998) 713-720
16. Sharma A.M., Pischon T., Hardt S., Kunz I., and Luft S.C. β-adrenergic receptor blockers and weight gain. A systematic analysis. Hypertension 37 (2001) 250-254
17. Kunz I., Schorr U., Klaus S., and Sharma A.M. Resting metabolic rate and substrate use in obesity hypertension. Hypertension 36 (2000) 26-32
18. Buemann B., Astrup A., Madsen J., and Christensen N.J. A 24-hour energy expenditure study on reduced-obese and nonobese women: effect of beta-blockade. Am J Clin Nutr 56 (1992) 662-670
19. Van Baak M.A., Bohm R.O., Arends B.G., van Hooff M.E., and Rahn K.H. Long-term antihypertensive therapy with beta-blockers: submaximal exercise capacity and metabolic effects during exercise. Int J Sports Med 8 (1987) 342-347
20. Welle S., Schwartz R.G., and Statt M. Reduced metabolic rate during beta-adrenergic blockade in humans. Metabolism 40 (1991) 619-622
21. Astrup A., Simonsen L., Bulow J., Madsen J., and Christensen N.J. Epinephrine mediates facultative carbohydrate-induced thermogenesis in human skeletal muscle. Am J Physiol 257 (1989) E340-E345
22. Koch G., Franz I.W., and Lohmann F.W. Effects of short-term and long-term treatment with cardio-selective and non-selective beta-receptor blockade on carbohydrate and lipid metabolism and on plasma catecholamines at rest and during exercise. Clin Sci 61 (1981) S433-S435
23. Gress T.W., Nieto F.J., Shahar E., Woffard M.R., and Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 342 (2000) 905-912
24. Barzilay J.I., Davis B.R., Cutler J.A., Pressel S.L., Whelton P.K., Basile J., et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment. A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 166 (2006) 2191-2201
25. Scheen A.J. VALUE: analysis of results. [letter]. Lancet 364 (2004) 932-933
26. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 (2002) 995-1003
27. Engeli S., Böhnke J., Gorzelniak K., Janke J., Schling P., Bader M., et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45 (2005) 356-362
28. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21 (2000) 697-738
29. Sharma A.M., and Staels B. Review: peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 92 (2007) 386-395
30. Janke J., Engeli S., Gorzelniak K., Luft F.C., and Sharma A.M. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin-type 1 receptors. Diabetes 51 (2002) 1699-1707
31. Gorzelniak K., Engeli S., Janke J., Luft F.C., and Sharma A.M. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 20 (2002) 965-973
32. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114 (2004) 1752-1761
33. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 43 (2004) 993-1002
34. Shimabukuro M., Tanaka H., and Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 25 (2007) 841-848
35. Sharma A.M., Davidson J.A., Gavin III J.R., and DeSousa N.J. Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs. valsartan/hydrochlorothiazide in high-risk overweight/obese patients with hypertension and type 2 diabetes. Hypertension 46 (2005) 898-899